Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TRV 027

Drug Profile

TRV 027

Alternative Names: Beta-arrestin biased ligand - Trevena; MPS-418; TRV-120027; TRV027; β-arrestin biased ligand - Trevena

Latest Information Update: 28 Jul 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Trevena
  • Developer Imperial College of Science, Technology and Medicine; National Heart, Lung and Blood Institute; Trevena
  • Class Heart failure therapies; Oligopeptides; Vasodilators
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Beta-arrestin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III COVID 2019 infections
  • Phase I Blood coagulation disorders
  • Preclinical SARS-CoV-2 acute respiratory disease
  • Discontinued Acute heart failure

Most Recent Events

  • 26 Jul 2021 Phase-II/III clinical trials in COVID-2019 infections in USA (IV)
  • 14 Jun 2021 Vanderbilt University Medical Center and National Institutes of Health plans the phase II/III NECTAR (ACTIV-4 Host Tissue) trial in COVID-2019 infections in USA (NCT04924660)
  • 01 Jun 2021 Trevena has two patent protections for covering crystalline forms and methods of synthesizing TRV 027 in the USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top